Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Myung-Ki Seo, MD
- Phone Number: 82-2-2072-3757
- Email: clotinab@gmail.com
Study Contact Backup
- Name: Hyun-Jae Kang, Prof
- Phone Number: 82-2-2072-2279
- Email: nowkang@snu.ac.kr
Study Locations
-
-
-
Seoul, South Korea
- Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- non-ST segment elevation acute myocardial infarction
- within 48 hours presence of chest pain
- Troponin-T or I positive before CAG
- First myocardial infarction
- will be performed coronary angioplasty
Exclusion Criteria:
- under 18 years of age,80 years or older
- Bleeding tendency
- History of major surgery within 4 weeks
- Major stroke within 2 years
- Thrombocytopenia (<120,000 / uL)
- Cardiogenic shock
- Known allergy to aspirin, heparin, or abciximab
- Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc)
- Chronic atrial fibrillation
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Abciximab IC bolus
After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg
body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
|
patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg
body weight,continus 12hrs-0.125ug/kg
per minute(maximum: 10ug/min)
|
|
Active Comparator: Abciximab IV bolus and 12hr continuous
|
patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg
body weight,continus 12hrs-0.125ug/kg
per minute(maximum: 10ug/min)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In cardiac MRI- infarct size (total late enhancement volume at day 3-7)
Time Frame: day 3~7 after percutaneous coronary intervention
|
MRI: magnetic resonance image
|
day 3~7 after percutaneous coronary intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
in-hospital and after 1-months:the major adverse cardiovascular events : death, myocardial infarction, hospitalization for heart failure, myocardial ischemia, etc.
Time Frame: 1 month
|
1 month
|
|
|
b. major bleeding : Hemoglobin 4 or more reduction, 2-unit If you need more than two RBC transfusions, intracranial or retroperitoneal bleeding, urgent operation for bleeding complication.
Time Frame: 1 month
|
RBC: red blood cell
|
1 month
|
|
TIMI III flow count /myocardial blush score after PCI
Time Frame: 1 day
|
TIMI: thrombolysis in myocardial infarction PCI: percutaneous coronary intervention
|
1 day
|
|
At cardiac MRI : LV ejection fraction,LV end-systolic volume,LV end diastolic volume,regional wall motion score index
Time Frame: 1 week
|
LV: left ventricle
|
1 week
|
|
Discharge, 1- month after comparing NT-proBNP
Time Frame: 1 month
|
NT-proBNP : N-terminal pro-B-Type natriuretic peptide
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Hyun-Jae Kang, Prof, Assistant professor, Cardiology, Department of internal medicine,Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Infarction
- Necrosis
- Myocardial Ischemia
- Ischemia
- Pathological Conditions, Signs and Symptoms
- Myocardial Infarction
- Peptides
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Immunoglobulin Fragments
- Peptide Fragments
- Immunoglobulin Fab Fragments
- Abciximab
Other Study ID Numbers
Other Study ID Numbers
- H-0906-046-283
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.